Chongqing biologics developer working on monoclonal antibody drugs including a denosumab-type bone-disease biosimilar.
Chongqing biologics developer working on monoclonal antibody drugs including a denosumab-type bone-disease biosimilar.
In one line: A small Chinese biologics/biosimilar developer.
Moat: none (IP / patents). Early-stage biologics portfolio still dependent on regulatory approval and reimbursement.
Headquarters: Chongqing, China · Employees: 984
Size Chongqing Genrix Biopharmaceutical (688443.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 1869th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.35 on 18 Nov 2026.
Performance Over six months the shares fell 22.3%, against -11.8% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 255.7% over the last twelve months (peer median -1.5%); the operating margin is -26.9% (peer median 0.8%).
Valuation It trades at 8.6× enterprise value to sales against a peer median of 7.6× (8th most expensive of 18).
Capital Return on invested capital runs 25.8 points below its cost of capital (8.1% WACC).
Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥801M | CN¥230M | CN¥29.8M | CN¥1.18M | CN¥106,041 |
| Revenue growth | — | +673% | +2,435% | +1,009% | — |
| Gross profit | CN¥690M | CN¥149M | -CN¥50.1M | -CN¥63.3M | -CN¥54.0M |
| EBITDA | n/a | -CN¥507M | -CN¥767M | -CN¥731M | -CN¥558M |
| Net income | -CN¥209M | -CN¥536M | -CN¥797M | -CN¥801M | -CN¥576M |
| Free cash flow | -CN¥296M | -CN¥415M | -CN¥621M | -CN¥469M | -CN¥320M |
| Capital expenditure | CN¥105M | CN¥85.4M | CN¥45.3M | CN¥91.0M | CN¥146M |
| Total debt | CN¥927M | CN¥1.06B | CN¥837M | CN¥641M | CN¥782M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical 688443.SS | $1.18B | -22% | +256% | -27% | 8.6× | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Shanghai Henlius Biotech 2696.HK | $3.05B | -39% | +33% | 12% | 3.3× | 14.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688443.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.6% | -3.4% | 9th highest of 21 |
| 6-month return | -22.3% | -11.8% | 9th lowest of 20 |
| Distance from 52-week high | -28.9% | -39.3% | 7th highest of 21 |
| Revenue growth (TTM) | +255.7% | -1.5% | highest of 18 |
| Operating margin | -26.9% | 0.8% | 7th lowest of 18 |
| EV / Sales | 8.6× | 7.6× | 8th most expensive of 18 |
| ROIC minus cost of capital | -25.8 pp | -7.5 pp | 6th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | 13.3× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 8.2× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 1.2× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 2.9× | 36.3% | +20.4% |